119:s:1097 — Interagency Patent Coordination and Improvement Act of 2025

Sponsor

Introduced by

Richard J. Durbin

D Democrat · Senate · IL D+6

Ranking Member · Senate Committee on the Judiciary

Latest action

Placed on Senate Legislative Calendar under General Orders. Calendar No. 41.

Action timeline

Every recorded action on this bill, newest first. Stage badges color-code the legislative path.

Apr 10, 2025

committee Committee on the Judiciary. Reported by Senator Grassley with amendments. Without written report.

Judiciary Committee

Apr 10, 2025

other Placed on Senate Legislative Calendar under General Orders. Calendar No. 41.

Apr 03, 2025

committee Committee on the Judiciary. Ordered to be reported with amendments favorably.

Judiciary Committee

Mar 24, 2025

introduced Introduced in Senate

Mar 24, 2025

introduced Read twice and referred to the Committee on the Judiciary. (text: CR S1804-1805)

Judiciary Committee

Text versions

Each stage of the bill — official text published by GPO. Click any format to read on congress.gov / govinfo.

Apr 10, 2025 Reported to Senate

XML

Mar 24, 2025 Introduced in Senate

XML

CRS summaries

Plain-English summaries written by the Congressional Research Service — neutral, nonpartisan staff who summarize bills as they advance through stages. The authoritative description of what each version of the bill does.

00 Introduced in Senate Mar 24, 2025

Interagency Patent Coordination and Improvement Act of 2025 This bill establishes the Interagency Task Force on Patents to support coordination and communication between the U.S. Patent and Trademark Office (USPTO) and the Food and Drug Administration (FDA) on activities relating to patents for human drugs and biological products. The task force's duties shall include sharing information about (1) the processes of each agency, including how each agency evaluates applications (e.g., patent applications at the USPTO and new drug applications at the FDA); and (2) new approvals of patents, human drugs, biological products, and new technologies. The task force must also establish a process that requires (1) the USPTO to request from the FDA information relating to certain patent applications to help patent examiners carry out their duties, (2) the FDA to provide such information to the USPTO, and (3) the USPTO to assist the FDA in its ministerial role of listing patents.

via Congressional Research Service · published through congress.gov

Changelog

ⓘ

How a bill moves through Congress. Each stage produces a new official text. The diff between them shows what changed at that step.

`ih` / `is` — Introduced in House / Senate. First filed version.

`rfh` / `rfs` — Referred to a committee for review.

`rh` / `rs` — Reported back by the committee to the floor (often with amendments — this is where most language changes happen).

`pcs` / `pch` — Placed on Calendar for floor consideration.

`eh` / `es` — Engrossed. Passed by the originating chamber. Text is now what was actually voted on.

`rdh` / `rds` — Received by the other chamber.

`eah` / `eas` — Engrossed Amendment. The other chamber passed an amended version.

`ath` / `ats` — Agreed to. Both chambers settled on the same text.

`enr` — Enrolled. Final reconciled text, sent to the President.

`pl` — Public Law. Signed by the President. It's now law.

`pp` — Public Print. Official printing post-enactment.

Most bills die before `eh`/`es`. Going from `pcs` → `enr` is the full path through both chambers.

Line-level diff between text versions of this bill — what actually changed at each legislative stage.

+34 −6 33 unchanged

--- Introduced (Senate)

+++ Reported (Senate)

@@ -1,8 +1,9 @@

[From the U.S. Government Publishing Office]

-[S. 1097 Introduced in Senate (IS)]

+[S. 1097 Reported in Senate (RS)]

<DOC>

+Calendar No. 41

119th CONGRESS

1st Session

S. 1097

@@ -22,6 +23,11 @@

Mr. Durbin (for himself, Mr. Tillis, Mr. Grassley, Mr. Coons, and Mr.

Welch) introduced the following bill; which was read twice and referred

to the Committee on the Judiciary

+

+April 10, 2025

+

+Reported by Mr. Grassley, with amendments

+[Omit the parts struck through and insert the parts printed in italic]

_______________________________________________________________________

@@ -72,7 +78,7 @@

(A) information is provided by the Food and Drug

Administration to the United States Patent and

Trademark Office through the Interagency Task Force on

-Patents established under section 15 of title 35,

+Patents established under section 15 14 of title 35,

United States Code, as added by section 4(a) of this

Act, or under processes established by that Task Force;

and

@@ -101,13 +107,13 @@

section relating to patents, and decisions or actions involving

patents, for human drugs and biological products, the Director shall,

through the Interagency Task Force on Patents established under section

-15, consult with the Commissioner of Food and Drugs in the manner

+15 14, consult with the Commissioner of Food and Drugs in the manner

described in that section.

``(B) For purposes of subparagraph (A), the term `decisions or

actions involving patents' means decisions or actions taken with

respect to patents under this title.''; and

(2) by adding at the end the following:

-``Sec. 15. Interagency Task Force on Patents

+``Sec. 1514. Interagency Task Force on Patents

``(a) Establishment.--There is established an interagency task

force, to be known as the Interagency Task Force on Patents (referred

to in this section as the `task force'), to coordinate efforts between

@@ -233,5 +239,27 @@

chapter 1 of title 35, United States Code, is amended by adding at the

end the following:

-``15. Interagency Task Force on Patents.''.

-<all>

+``1514. Interagency Task Force on Patents.''.

+Calendar No. 41

+

+119th CONGRESS

+

+1st Session

+

+S. 1097

+

+_______________________________________________________________________

+

+A BILL

+

+To amend title 35, United States Code, to establish an interagency task

+force between the United States Patent and Trademark Office and the

+Food and Drug Administration for purposes of sharing information and

+providing technical assistance with respect to patents, and for other

+purposes.

+

+_______________________________________________________________________

+

+April 10, 2025

+

+Reported with amendments

Lobbying activity

Organizations whose LDA filings reference this bill, ranked by filing count. Position not disclosed — LDA does not require lobbyists to report support / oppose / monitor. Bill-number references can be stale (lobbyists sometimes copy text year-over-year), so verify against the filing description.

NOVARTIS

CPT

7

filings · 2026 Q3

COUNCIL FOR INNOVATION PROMOTION (C4IP)

CPT

7

filings · 2026 Q3

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

CPT

5

filings · 2026 Q3

JOHNSON & JOHNSON SERVICES INC

CPT

5

filings · 2026 Q3

GSK (FKA GLAXOSMITHKLINE INC.)

CPT

5

filings · 2025 Q3

TEVA PHARMACEUTICALS USA, INC.

CPTHCR

5

filings · 2026 Q3

COUNCIL FOR INNOVATION PROMOTION (C4IP)

CPT

5

filings · 2026 Q3

THE CAMPAIGN FOR SUSTAINABLE RX PRICING

CPT

5

filings · 2026 Q3

CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP)

CPT

5

filings · 2026 Q3

AMERICAN INTELLECTUAL PROPERTY LAW ASSOCIATION (AIPLA)

CPT

5

filings · 2026 Q3

via Senate LDA · self-reported quarterly. Filing count = filings mentioning this bill (no position required), not money spent on it. Click a client to see all bills they've filed on.

Cosponsors (4)

Members who signed on to support this bill.